Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 1.00 |
| ▸ | TDO2 | P48775 | 3/20 | 0.42 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915865 | 0.89 | IDO1 (0.80) | IDO1ALDH1A1 | |
| SCHEMBL19915804 | 0.79 | IDO1 (1.00) | IDO1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL19915982 | 0.77 | IDO1 (0.68) | IDO1 | |
| SCHEMBL21120859 | 0.76 | IDO1 (0.71) | IDO1 | |
| SCHEMBL19915828 | 0.76 | IDO1 (1.00) | IDO1ALDH1A1 | |
| SCHEMBL21060527 | 0.76 | IDO1 (0.66) | IDO1TDO2 | |
| SCHEMBL21094895 | 0.75 | IDO1 (0.61) | IDO1 | |
| SCHEMBL19915718 | 0.72 | IDO1 (0.64) | IDO1 | |
| SCHEMBL19915973 | 0.72 | IDO1 (0.64) | IDO1 | |
| SCHEMBL19915730 | 0.72 | IDO1 (0.78) | IDO1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689652-B | Fused heterocyclic derivative, preparation method and medical application thereof | 北京诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| WO-2018036414-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 北京诺诚健华医药科技有限公司 | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | IDO1, IDO2, INMT | IDO1 1/4885TDO2 49/4885WNK1 137/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | IDO1 1/4885TDO2 49/4885WNK1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.